357 related articles for article (PubMed ID: 31175097)
21. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.
Xiao X; Wang W; Zhang H; Gao P; Fan B; Huang C; Fu J; Chen G; Shi L; Zhu H; Li X; Li J; Fan H; Wu Z; Guo Z; Hu Y; Wu S; Yu X; Xu C; Wang Z
Tumour Biol; 2015 Apr; 36(4):2427-35. PubMed ID: 25431261
[TBL] [Abstract][Full Text] [Related]
22. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
23. Genomic alterations in neuroendocrine cancers of the ovary.
Yaghmour G; Prouet P; Wiedower E; Jamy OH; Feldman R; Chandler JC; Pandey M; Martin MG
J Ovarian Res; 2016 Aug; 9(1):52. PubMed ID: 27566252
[TBL] [Abstract][Full Text] [Related]
24. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
Lam VK; Tran HT; Banks KC; Lanman RB; Rinsurongkawong W; Peled N; Lewis J; Lee JJ; Roth J; Roarty EB; Swisher S; Talasaz A; Futreal PA; Papadimitrakopoulou V; Heymach JV; Zhang J
Clin Lung Cancer; 2019 Jan; 20(1):30-36.e3. PubMed ID: 30279110
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.
Attalla K; DiNatale RG; Rappold PM; Fong CJ; Sanchez-Vega F; Silagy AW; Weng S; Coleman J; Lee CH; Carlo MI; Durack JC; Solomon SB; Reuter VE; Russo P; Chan TA; Motzer RJ; Schultz ND; Reznik E; Voss MH; Hakimi AA
Clin Cancer Res; 2021 Oct; 27(20):5595-5606. PubMed ID: 34261695
[TBL] [Abstract][Full Text] [Related]
26. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
[TBL] [Abstract][Full Text] [Related]
27. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
[TBL] [Abstract][Full Text] [Related]
29. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
30.
Hou H; Jia D; Yan W; Zhang X; Wang C; Li Y; Chen H; Huang W; Li Z; Zhang X
Transl Cancer Res; 2020 Aug; 9(8):4703-4714. PubMed ID: 35117834
[TBL] [Abstract][Full Text] [Related]
31. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma.
Lau CC; Harris CP; Lu XY; Perlaky L; Gogineni S; Chintagumpala M; Hicks J; Johnson ME; Davino NA; Huvos AG; Meyers PA; Healy JH; Gorlick R; Rao PH
Genes Chromosomes Cancer; 2004 Jan; 39(1):11-21. PubMed ID: 14603437
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
33. Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.
Zhang HQ; Li MH; Gao P; Lan PH; Fan B; Xiao X; Lu YJ; Chen GJ; Wang Z
Orthop Surg; 2016 May; 8(2):129-38. PubMed ID: 27384721
[TBL] [Abstract][Full Text] [Related]
34. Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma.
Yang JL
Chin J Cancer; 2014 Dec; 33(12):575-80. PubMed ID: 25418192
[TBL] [Abstract][Full Text] [Related]
35. Comparative genomic hybridization of low-grade central osteosarcoma.
Tarkkanen M; Böhling T; Gamberi G; Ragazzini P; Benassi MS; Kivioja A; Kallio P; Elomaa I; Picci P; Knuutila S
Mod Pathol; 1998 May; 11(5):421-6. PubMed ID: 9619593
[TBL] [Abstract][Full Text] [Related]
36. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification.
Guérin M; Thariat J; Ouali M; Bouvier C; Decouvelaere AV; Cassagnau E; Aubert S; Lepreux S; Coindre JM; Valmary-Degano S; Larousserie F; Meilleroux J; Projetti F; Stock N; Galant C; Marie B; Peyrottes I; de Pinieux G; Gomez-Brouchet A
Hum Pathol; 2016 Apr; 50():70-8. PubMed ID: 26997440
[TBL] [Abstract][Full Text] [Related]
37. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
38. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
39. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
[TBL] [Abstract][Full Text] [Related]
40. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]